// Medical Therapy for NF2-related Schwannomatosis: A Systematic Review of Current Evidence
本系統性回顧評估NF2相關聽神經鞘瘤的醫療治療，重點在於腫瘤控制與聽力改善｜貝伐單抗（Bevacizumab）效果最佳，提升最多61%患者聽力，並使腫瘤縮小達60%｜其他如mTOR抑制劑、酪氨酸激酶抑制劑及VEGFR疫苗效果不一，需更多隨機試驗驗證療效與持久性。
// This systematic review evaluated medical treatments for NF2-related vestibular schwannomas, focusing on tumor control and hearing outcomes. Bevacizumab showed the most consistent benefits, improving hearing in up to 61% of patients and reducing tumor size in up to 60%. Other therapies like mTOR inhibitors, tyrosine kinase inhibitors, and VEGFR vaccines had variable and less consistent results. The study highlights the need for high-quality randomized trials to better assess these treatments' efficacy and durability.
Published 2026年6月11日
// 正在尋找相關文獻...